Multidrug-resistant tuberculosis

Multidrug-resistant tuberculosis
Name	Multidrug-resistant tuberculosis
Field	Infectious disease
Symptoms	cough, fever, weight loss, night sweats
Complications	respiratory failure, systemic dissemination
Onset	weeks to months after infection
Causes	Mycobacterium tuberculosis drug resistance
Risks	prior treatment, HIV/AIDS, Diabetes mellitus
Diagnosis	drug susceptibility testing, molecular assays
Treatment	second-line antimicrobials, prolonged therapy
Deaths	variable by region

Multidrug-resistant tuberculosis is a form of tuberculosis caused by strains of Mycobacterium tuberculosis that are resistant to at least isoniazid and rifampicin, two cornerstone antitubercular drugs. It poses clinical and public health challenges across regions such as India, South Africa, Russia, China, and Brazil, complicating care pathways established by programmes like the World Health Organization and national agencies including Centers for Disease Control and Prevention and Public Health England. Management intersects with programmes administered by United Nations entities, nongovernmental organizations such as Médecins Sans Frontières, and funding mechanisms like the Global Fund.

Overview

The clinical syndrome stems from drug-resistant Mycobacterium lineages that undermine standardized regimens deployed under initiatives like the DOTS strategy and policies endorsed by the Stop TB Partnership. Presentation mirrors drug-susceptible tuberculosis described in classical texts and cases associated with outbreaks in settings such as prison systems and urban slums documented in reports by Amnesty International and Human Rights Watch. Health system responses often involve coordination between ministries exemplified by Ministry of Health (India), provincial bodies such as KwaZulu-Natal Department of Health, and international collaborators including World Bank–supported programmes.

Causes and Mechanisms of Resistance

Resistance emerges through chromosomal mutations in targets of drugs including mutations in genes catalogued by research groups at institutions like Harvard Medical School, University of Oxford, Karolinska Institutet, and University of Cape Town. Mechanisms include alterations in drug-activating enzymes and efflux systems characterized in studies from laboratories associated with National Institutes of Health, Institut Pasteur, and Wellcome Trust–funded centres. Inadequate treatment regimens traced to policies of national programmes such as those in Philippines or Ukraine and operational failures reported by Centers for Disease Control and Prevention contribute, while comorbidities like HIV/AIDS and Diabetes mellitus influence selection pressures discussed in papers from Johns Hopkins University and Imperial College London.

Diagnosis

Laboratory confirmation employs molecular tests developed by companies and institutions such as Cepheid, WHO-endorsed platforms, and reference laboratories like Public Health England and the National Reference Laboratory (Russia). Techniques include nucleic acid amplification tests, whole-genome sequencing initiatives led by teams at Wellcome Sanger Institute and Broad Institute, and phenotypic drug susceptibility testing performed in networks coordinated by European Centre for Disease Prevention and Control and Asian Pacific Economic Cooperation health forums. Clinical algorithms adapted by ministries in South Africa and Indonesia integrate radiology services found in tertiary centres such as Groote Schuur Hospital and diagnostic contributions from institutions like Mayo Clinic.

Treatment and Management

Treatment uses second-line drugs guided by protocols from World Health Organization and national guidelines such as those from Centers for Disease Control and Prevention. Regimens may incorporate agents approved by regulatory bodies including the U.S. Food and Drug Administration and recommended by advisory panels convened at National Institute for Health and Care Excellence. Delivery models draw on community programmes run by Médecins Sans Frontières and patient support frameworks employed by International Red Cross and Red Crescent Movement. Multidisciplinary care often involves specialists trained at centres like Massachusetts General Hospital and Rigshospitalet addressing adverse effects, surgical interventions pioneered in publications from Mayo Clinic and Johns Hopkins Hospital, and psychosocial support models promoted by World Bank–funded projects.

Epidemiology and Public Health Impact

Burden assessments are reported in global reports by World Health Organization, national surveillance from Russia, China, South Africa, India, and analytic work by research groups at Imperial College London and University of California, San Francisco. Outbreak investigations in congregate settings such as facilities described in Eastern State Penitentiary–type studies and series from urban centres like Mumbai illustrate transmission dynamics. Economic and societal impacts are discussed in analyses by World Bank, Organisation for Economic Co-operation and Development, and nonstate actors including Gates Foundation grant recipients. Mortality and morbidity data feed into global health metrics used by United Nations Development Programme and public health observatories maintained by European Public Health Association.

Prevention and Control Strategies

Control strategies follow frameworks advocated by World Health Organization, operationalized through collaborations with Stop TB Partnership, funding via the Global Fund, and technical support from Centers for Disease Control and Prevention. Interventions include rapid diagnostics deployed in programs supported by Bill & Melinda Gates Foundation and vaccine research partnerships involving PATH and academic consortia at London School of Hygiene & Tropical Medicine. Infection control in healthcare settings references guidelines from Occupational Safety and Health Administration and facility-level protocols used at Groote Schuur Hospital and St. Thomas' Hospital. Social protection measures draw on models implemented by Brazil's Bolsa Família–related health initiatives and conditional cash transfer evaluations funded by Inter-American Development Bank.

Research and Future Directions

Ongoing research spans drug development led by consortia including TB Alliance and pharmaceutical firms regulated by European Medicines Agency and U.S. Food and Drug Administration, vaccine trials coordinated with sites like South African Tuberculosis Vaccine Initiative and academic partners at University of Oxford. Genomic surveillance networks link institutes such as Wellcome Sanger Institute, Broad Institute, and national reference laboratories in Russia and China. Implementation science projects funded by Wellcome Trust and executed with partners like Médecins Sans Frontières and World Health Organization aim to integrate new regimens into public programmes modeled on pilots in Peru, Georgia (country), and Mongolia. Policy dialogues convened by United Nations fora and health summits foster resource mobilization through the Global Fund and bilateral partnerships with agencies such as United States Agency for International Development.

Category:Tuberculosis